Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

261. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. (Abstract)

Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. Previously, we compared fixed low doses of heparin with adjusted doses of warfarin for the long-term treatment of venous thrombosis; in that study low-dose heparin was ineffective in preventing recurrence in patients with proximal-vein thrombosis. We have now completed a randomized trial comparing adjusted doses of heparin and of warfarin for prevention of recurrent venous thromboembolism (...) in patients with proximal-vein thrombosis. One hundred six consecutive patients with acute proximal-vein thrombosis confirmed by venography were treated with intravenous heparin and then randomized to secondary prophylaxis. Two of 53 patients receiving heparin, as compared with one of 53 receiving warfarin, had new episodes of objectively documented venous thromboembolism. Nine patients taking warfarin had bleeding complications (which were major in three patients), as compared with one patient taking

1982 NEJM Controlled trial quality: uncertain

262. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. (Abstract)

Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. In a controlled, randomized study, survival of patients with small cell carcinoma of the lung (SCCL) was prolonged on addition of warfarin sodium to combination chemotherapy plus radiation therapy. Median survival for 25 control patients was 24 weeks and for 25 warfarin-treated patients was 50 weeks. This difference could not be accounted for by differences between groups in performance (...) status, extent of disease, age, or sex. The survival advantage associated with warfarin administration was observed both for patients with extensive disease and for those who failed to achieve complete or partial remission. The warfarin-treated group also demonstrated a significantly increased time to first evidence of disease progression. These results suggest that warfarin may be useful in the treatment of SCCL and also support the hypothesis that the blood coagulation mechanism may be involved

1981 JAMA Controlled trial quality: uncertain

263. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. (Abstract)

Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. Acute deep-vein thrombosis is usually treated with intravenous heparin for a number of days, then with oral anticoagulants for weeks to months. We have compared adjusted-dose warfarin sodium with fixed low-dose subcutaneous heparin in the prevention of recurrent deep-vein thrombosis. Sixty-eight patients with acute deep-vein thrombosis confirmed by venography were treated with intravenous heparin (...) and then randomized to secondary prophylaxis. Nine of 35 patients receiving subcutaneous heparin, but none of 33 receiving warfarin sodium, had new episodes of objectively documented venous thromboembolism (P = 0.001). Seven patients on warfarin sodium experienced bleeding complications (of which four were major), as compared with no patients receiving subcutaneous heparin (P less than 0.005). Thus, adjusted-dose warfarin sodium is more effective than low-dose subcutaneous heparin in preventing recurrent venous

1979 NEJM Controlled trial quality: uncertain

264. Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. (Abstract)

Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. In a prospective controlled randomised trial, the prophylactic value of warfarin sodium (in doses aimed at maintaining a "Thrombotest" value of 10% and given from the day of admission until independent mobility had been achieved or for 3 mo, whichever was the sooner) was assessed in 160 elderly patients who had sustained a fracture of the femoral neck. Treatment significantly

1976 Lancet

265. Interaction of sodium warfarin and rifampin. Studies in man. (Abstract)

Interaction of sodium warfarin and rifampin. Studies in man. 4852505 1974 11 07 2013 11 21 0003-4819 81 3 1974 Sep Annals of internal medicine Ann. Intern. Med. Interaction of sodium warfarin and rifampin. Studies in man. 337-40 O'Reilly R A RA eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 5Q7ZVV76EI Warfarin VJT6J7R4TR Rifampin AIM IM Administration, Oral Adult Drug Antagonism Humans Injections, Intravenous Male (...) Middle Aged Prothrombin Time Rifampin pharmacology Warfarin administration & dosage antagonists & inhibitors blood metabolism 1974 9 1 1974 9 1 0 1 1974 9 1 0 0 ppublish 4852505

1974 Annals of Internal Medicine Controlled trial quality: uncertain

266. Prothrombin levels maintained with meprobamate and warfarin. A controlled study. (Abstract)

Prothrombin levels maintained with meprobamate and warfarin. A controlled study. 4623950 1972 07 29 2016 10 17 0098-7484 220 11 1972 Jun 12 JAMA JAMA Prothrombin levels maintained with meprobamate and warfarin. A controlled study. 1460-2 Gould L L Michael A A Fisch S S Gomprecht R F RF eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Placebos 5Q7ZVV76EI Warfarin 9001-26-7 Prothrombin 9I7LNY769Q Meprobamate AIM IM Adult Aged (...) Animals Clinical Trials as Topic Dogs Drug Interactions Female Humans Long-Term Care Male Meprobamate administration & dosage metabolism therapeutic use Microsomes, Liver enzymology Middle Aged Placebos Prothrombin Prothrombin Time Rats Time Factors Warfarin administration & dosage metabolism therapeutic use 1972 6 12 1972 6 12 0 1 1972 6 12 0 0 ppublish 4623950

1972 JAMA Controlled trial quality: uncertain

267. Prevention of venous thromboembolism following total hip replacement. Warfarin vs dextran 40. (Abstract)

Prevention of venous thromboembolism following total hip replacement. Warfarin vs dextran 40. 5067322 1972 07 08 2016 11 22 0098-7484 220 10 1972 Jun 05 JAMA JAMA Prevention of venous thromboembolism following total hip replacement. Warfarin vs dextran 40. 1319-22 Harris W H WH Salzman E W EW DeSanctis R W RW Coutts R D RD eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Dextrans 5Q7ZVV76EI Warfarin 9NEZ333N27 Sodium AIM IM (...) Adult Age Factors Aged Dextrans administration & dosage Evaluation Studies as Topic Female Hematocrit Hip surgery Hip Joint Hospitalization Humans Injections, Intramuscular Joint Prosthesis Length of Stay Male Middle Aged Postoperative Complications Prospective Studies Prothrombin Time Sodium administration & dosage Thrombophlebitis prevention & control Warfarin administration & dosage adverse effects 1972 6 5 1972 6 5 0 1 1972 6 5 0 0 ppublish 5067322

1972 JAMA Controlled trial quality: uncertain